BioCentury | Apr 1, 2021
Product Development

April 1 Quick Takes: BioNTech, Pfizer to seek full approval of vaccine; plus CEPI’s call and FDA’s latest batch of expanded labels

...WHO Group 3) to improve exercise ability. It was first approved in 2009 to treat PAH...
BioCentury | Mar 6, 2021
Product Development

March 5 Quick Takes: A regulatory first for Actemra; plus updates from Lilly-Incyte, Kronos, Junshi, United Therapeutics, Pfizer, Sumitomo Dainippon, Arena, Oyster Point, Azura

...said FDA’s latest action confers full approval on Lorbrena.End of the road for United Therapeutics’ PAH...
BioCentury | Jan 30, 2021
Distillery Therapeutics

SLC12A5, Rho kinase as targets for mutation-associated intellectual disability

...and Eisai also have the product in Phase II testing to treat pulmonary arterial hypertension (PAH).D...
BioCentury | Dec 31, 2020

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

...inhaler —to treat pulmonary arterial hypertension (PAH...
BioCentury | Dec 21, 2020

Agios to exit oncology, reward investors via Servier deal as lead anemia program nears submission

...PKR activation has applications in more than 20 indications. Agios also has preclinical programs targeting PAH...
BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

...and interventional radiology at Stanford University and was CMO at Graybug Vision Inc. (NASDAQ:GRAY).Setback for Liquidia PAH...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH...
BioCentury | Sep 17, 2020

Ahead of R&D day, Moderna unveils two rare disease deals

...initiated a collaboration with Chiesi Farmaceutici S.p.A. to develop mRNA therapies for pulmonary arterial hypertension (PAH).From...
BioCentury | Aug 13, 2020
Emerging Company Profile

RA-incubated Aerovate to deploy $72.6M series A for inhaled imatinib for PAH

...A round to support clinical testing of an inhaled dry powder formulation of imatinib for PAH...
...the core issue of proliferation. When Novartis AG (NYSE:NVS; SIX:NOVN) took cancer drug Gleevec imatinib through Phase III testing in PAH...
...found that the antiproliferative tyrosine kinase inhibitor significantly improved 6-minute walk (6MW) distance, the standard primary endpoint in PAH...
BioCentury | Jun 23, 2020

Vaccines deal with Sanofi to propel Translate Bio’s mRNA therapeutics platform

...lung delivery platform in additional pulmonary diseases, including primary ciliary dyskinesia (PDC), pulmonary arterial hypertension (PAH...
Items per page:
1 - 10 of 1362